Working… Menu

Study of IMC-EB10 in Participant With Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00887926
Recruitment Status : Terminated (Lack of efficacy)
First Posted : April 24, 2009
Results First Posted : September 11, 2019
Last Update Posted : September 11, 2019
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.

Condition or disease Intervention/treatment Phase
Myeloid Leukemia Biological: IMC-EB10 Phase 1

Detailed Description:
The purpose of this study is to define the maximum tolerated dose (MTD) and the pharmacokinetic (PK) profile of the anti-FMS-like tyrosine kinase 3 (FLT3) monoclonal antibody IMC-EB10, administered weekly in participant with acute lymphoblastic leukemia (AML) who have failed to achieve complete remission to a standard induction regimen, relapsed after response to previous antileukemia therapy, or are not eligible for potentially curative or approved salvage options.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Study Start Date : June 2009
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Arm Intervention/treatment
Experimental: IMC-EB10 5 milligrams/kilogram (mg/kg)
All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
Biological: IMC-EB10
Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
Other Name: LY3012218

Primary Outcome Measures :
  1. Maximum Tolerate Dose (MTD) of IMC-EB10 [ Time Frame: Cycle 1 (28-day cycle) ]
    MTD is defined as the dose preceding the dose level at which 2 participants experienced a dose limiting toxicity (DLT) during Cycle 1. DLT is defined using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v 3.0): (1) any Grade 3 or 4 toxicity that is clearly not attributable to leukemia [for example (e.g.) a type of end-organ failure that is infrequently encountered in acute myeloid leukemia (AML)] and is possibly, probably, or definitely attributable to IMC-EB10 in the judgment of the investigator; and (2) any Grade 3 or 4 toxicity that is clearly not attributable to a co-medication (e.g., prolonged neutropenia that is not attributable to hydroxyurea).

Secondary Outcome Measures :
  1. Pharmacokinetic (PK): Maximum Concentration (Cmax) [ Time Frame: Cycle 1 Week 1: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 96, and 168 h after infusion ends, and Cycle 1 Week 3: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycles) ]
  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Concentration [AUC(0-last)] [ Time Frame: Cycle 1 Week 1: predose, immediately after infusion, and at 1.5, 2, 4, 8, 24, 96 and 168 h after infusion ends (28-day cycle) ]
  3. PK: Area Under the Concentration Time Curve During the Dosing Interval (AUCtau) Where Tau is 168 Hours [ Time Frame: Cycle 1 Week 3: predose, immediately after infusion and at 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycle) ]
  4. Number of Participants With Adverse Events (AEs) (Safety Profile of IMC-EB10) [ Time Frame: 8 weeks and 30-day post-treatment follow-up ]
    Clinically significant events were defined as serious adverse events (SAEs) and other non-serious AEs regardless of causality. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module

  5. Number of Participants With Anti-IMC-EB10 Antibodies [ Time Frame: Cycle 1, Weeks 1 and 3 and Cycle 2, Week 1: predose (28-day cycles) ]
    A participant is considered positive for antibodies against IMC-EB10 if their blood sample exhibited a post-treatment antibody level that exceeds the positive upper cut point determined from the anti-IMC-EB10 level in healthy untreated individuals. A participant was considered to have an anti-IMC-EB10 response if there are 2 consecutive positive samples or if the final sample tested is positive.

  6. Number of Participants With Antileukemic Complete Response (CR) or Partial Response (PR) [ Time Frame: 4 weeks ]
    Assessment of antileukemic response was based on hematologic response criteria. PR defined as >1000/microliter (µL) neutrophils and ≥100000/µL platelets in peripheral blood; a decrease of ≥50% in the pretreatment percentage of blasts to 5% to 25% in the bone marrow aspirate or a value of ≤5% blasts if Auer rods are present. Cytogenetic CR defined as normal cytogenetic findings. Molecular CR defined as negative findings for minimal residual disease by automated quantitative Reverse-Transcription-Polymerase Chain Reaction (RT-PCR) and multidimensional flow cytometry. Morphologic CR with incomplete blood count recovery defined as ≤5% blasts (containing no Auer rods) in a bone marrow aspirate with spicules; neutrophil count < 1000/µL or platelets <100000/mL in peripheral blood or no extramedullary leukemia present.

  7. Number of Participants With Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 3 (FLT3) Response [ Time Frame: Week 4 and Week 8 ]
    FLT3 response to IMC-EB10 is defined as wild type, internal tandem duplications (ITD) mutations and other mutations.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The participant has acute myeloid leukemia in the bone marrow or blood that has relapsed with or without a prior complete remission
  2. The participant is not regarded to be a candidate for a potentially curative, higher priority treatment for acute myeloid leukemia
  3. The participant has resolution of all clinically significant toxic effects of any prior antitumor therapy and any other study-specific clinical or laboratory parameter specified in the entry criteria
  4. The participant has not had major surgery, an open biopsy, a significant injury, and/or prior antitumor therapy (except antileukemia therapy) within 21 days prior to the first infusion of IMC-EB10
  5. The participant has an Eastern Cooperative Oncology Group (ECOG)performance status of 0, 1, or 2 at study entry.
  6. The participant is age 18 years or older
  7. The participant has a life expectancy of >3 months
  8. The participant has adequate liver and kidney function, as defined in the entry criteria
  9. The participant is using an effective contraception (per the institutional standard), if procreative potential exists
  10. The participant is able to give written informed consent
  11. The participant is willing and able to comply with study procedures, scheduled visits, and treatment plans

Exclusion Criteria:

  1. The participant has had prior allogenic or autologous stem cell transplant within <3 months of the first infusion of IMC-EB10
  2. The participant has had an organ transplant (nonhematologic) within 3 years of study entry
  3. The participant has active central nervous system leukemia
  4. The participant has extramedullary disease without peripheral/and or bone marrow involvement
  5. The participant is disease-free from a previous or concurrent malignancy for a period ≤ 1 year. A participant who has basal cell carcinoma or carcinoma in situ of the cervix will not be excluded from the study
  6. The participant is currently receiving antileukemia therapy. Concurrent treatment with hydroxyurea is permitted
  7. The participant has uncontrolled intercurrent illness as specified in the study entry criteria
  8. The participant is receiving chronic steroid or other immunosuppressive medications. Occasional use of steroid-containing medications for, for example (e.g.), asthma exacerbation or for skin lesions, is permitted
  9. The participant is receiving full-dose heparin (including low molecular weight heparin) or warfarin. [The participant is permitted to use low-dose warfarin to maintain patency of preexisting, permanent, indwelling intravenous (I.V.) catheters.]
  10. The participant is pregnant (confirmed by urine or serum pregnancy test) or breast feeding
  11. The participant has received treatment with monoclonal antibodies within 6 weeks prior to first infusion of IMC-EB10
  12. The participant has a history of clinically significant allergic reactions to monoclonal antibodies or other therapeutic proteins

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00887926

Layout table for location information
United States, Ohio
ImClone Investigational Site
Columbus, Ohio, United States, 43210
United States, Texas
ImClone Investigational Site
Houston, Texas, United States, 77030
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: E-mail: ClinicalTrials@ Eli Lilly and Company
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT00887926    
Other Study ID Numbers: 13959
CP17-0801 ( Other Identifier: ImClone, LLC )
I5C-IE-JEBA ( Other Identifier: Eli Lilly and Company )
First Posted: April 24, 2009    Key Record Dates
Results First Posted: September 11, 2019
Last Update Posted: September 11, 2019
Last Verified: February 2012
Keywords provided by Eli Lilly and Company:
Acute Myeloid Leukemia
Antibodies, Monoclonal
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Neoplasms by Histologic Type